After 2022’s challenging capital markets environment, leaders in the technology and life sciences industries have set their sights on 2023 and beyond—evaluating the private fundraising market, looking for ways to extend their cash runway, considering strategic options and, in certain cases, taking steps to prepare for a potential public debut when the markets improve.
Please see full publication below for more information.
